Literature DB >> 8970475

Hydroxyurea treatment in HIV-infected patients.

C Simonelli, G Nasti, E Vaccher, U Tirelli, S Zanussi, P De Paoli, M Comar, M Giacca.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8970475     DOI： 10.1097/00042560-199612150-00011

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN： 1077-9450


× No keyword cloud information.
  6 in total

1.  Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients.

Authors:  Wei Cao; Zhi-Feng Qiu; Tai-Sheng Li
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

2.  Chronic myelogenous leukemia in an HIV-infected patient.

Authors:  X de la Tribonniere; R Leberre; I Plantier; S Alfandari; C Beuscart; J P Jouet; Y Mouton
Journal:  Infection       Date:  1998 May-Jun       Impact factor: 3.553

Review 3.  Pharmacokinetics and pharmacodynamics of hydroxyurea.

Authors:  P R Gwilt; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

4.  Hydroxyurea for the Treatment of Psoriasis including in HIV-infected Individuals: A Review.

Authors:  Eric S Lee; Misha M Heller; Faranak Kamangar; Kelly Park; Wilson Liao; John Koo
Journal:  Psoriasis Forum       Date:  2011

Review 5.  Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

Authors:  Julianna Lisziewicz; Andrea Foli; Mark Wainberg; Franco Lori
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

6.  The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants.

Authors:  Sarah W Read; Mary DeGrezia; Emily J Ciccone; Rebecca DerSimonian; Jeanette Higgins; Joseph W Adelsberger; Judith M Starling; Catherine Rehm; Irini Sereti
Journal:  PLoS One       Date:  2010-08-03       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.